At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 42 enrolled
Drug / intervention
Ravagalimab 600 mg +1 moredrug
Likely dose
Ravagalimab 600 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Single Arm, Open-label Study to Investigate the Efficacy and Safety of Ravagalimab (ABBV-323) in Subjects With Moderate to Severe Ulcerative Colitis Who Failed Prior Therapy
In Brief
A Phase 2 clinical trial evaluating Ravagalimab 600 mg and Ravagalimab 300 mg for Ulcerative Colitis (UC). Completed, enrolled 42 participants across 34 sites in 10 countries.
Detailed Summary
Study M15-722 is a Phase 2a study to investigate the efficacy and safety of Ravagalimab (ABBV-323) in participants with moderate to severe UC who failed prior therapy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsUlcerative Colitis (UC)
CountriesCanada, France, Germany, Hungary, Italy, Netherlands, South Korea, Spain, United Kingdom, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20192020202120222023202420252026
First PostedOct 2018
Enrollment StartMar 2019
Primary CompletionApr 2021
Study CompletionJan 2022
TodayJul 2026
First PostedOct 4, 2018
Enrollment StartMar 26, 2019
Primary CompletionApr 5, 2021
Study CompletionJan 10, 2022
TodayJul 2, 2026
Enrollment to primary: 2.0 yearsPosted 7.7 years ago
Interventions
Ravagalimab 600 mgdrug
Ravagalimab 600 mg was administered intravenously (IV).
Ravagalimab 300 mgdrug
Ravagalimab 300 mg was administered subcutaneously (SC).